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Background
The pathogenesis of Alzheimer's disease (AD) may
involve impaired clearance of toxic metabolites, e.g. amy-
loid-beta peptides (Aβ), from the brain via interstitial
fluid (ISF) and cerebrospinal fluid (CSF) circulation, and
the blood-brain barrier (BBB). If so, then increasing ISF
and CSF circulation may improve CSF Aβ clearance and
may slow the progression of AD. We tested this hypothesis
in a prospective, randomized, double-blind, placebo-con-
trolled trial of low-flow CSF shunting. Our previously
reported analysis using the Generalised Estimating Equa-
tions showed no effect of CSF shunting. The present
report provides post hoc analyses using linear mixed-
effects models fit by maximum likelihood.
Materials and methods
The study group consisted of 164 people with mild to
severe AD (baseline Mattis Dementia Rating Scale –
MDRS-scores 54–137). We administered the MDRS prior
to shunt implantation surgery (baseline, time = 0) and 3,
6, 9, and 12 months post-operatively. We also adminis-
tered the Alzheimer's Disease Cooperative Study Activities
of Daily Living Inventory (ADCS-ADL) at baseline and 9
months. Linear mixed-effects models fit by maximum
likelihood compared the rates of decline for the two
groups over the period of 3 to 12 months for the MDRS
and 0 to 9 months for the ADCS-ADL. In the MDRS model
we co-varied the baseline scores and incorporated random
effects and variance functions to adjust for heteroscedas-
ticity when estimating rates of decline.
Results
Rates of decline for both measures were less in the actively
shunted AD group. The MDRS rate of decline was 0.54 ±
0.25/month less than the control group (p = 0.031). The
ADCS-ADL rate of decline was 0.66 ± 0.33/month less
then the control group (p = 0.042). Variability in the
MDRS rate of decline in the active shunt group increased
with time, compared to controls (p < 0.001).
Conclusion
CSF shunting reduced rates of cognitive and functional
decline in patients with mild to severe AD. This supports
the hypothesis that impaired CSF clearance of toxic moie-
ties may contribute to the pathogenesis of AD. Mixed
effects models of cognitive decline may be more efficient
than marginal models, such as the Generalised Estimating
Equations. The increased variability in cognitive scores in
the group with active shunts may result from the benefi-
cial effects not occurring in some patients, and/or possibly
from unwanted side effects in a few individuals. Overall,
however, CSF shunting in mild to severe AD was benefi-
cial.
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